Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.7 (
plasmin
)
9,023
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Several new analogs of the known thrombin inhibitor
NAPAP
were synthesized, in which the P2 glycine residue was substituted by natural and unnatural amino acids. The thrombin inhibitory potency was comparable to that of
NAPAP
. Several of the compounds had inhibition constants lower than 10 nM and a very high selectivity compared to trypsin, factor Xa and
plasmin
. In addition, analogs were prepared by alkylation of the N alpha-atom of the 4-amidinophenylalanine in P1 position, which showed a more than 10-fold lower thrombin inhibition. Furthermore, azaglycine was introduced instead of P2 glycine. For most of the inhibitors similar fast elimination rates were seen in rats after intravenous dosing, as found previously for
NAPAP
. Only some compounds, which contained a second basic group showed a slightly decreased cumulative biliary clearance.
...
PMID:Structure-activity relationships of new NAPAP-analogs. 1242 Jul 61
Several new analogs of the known thrombin inhibitor
NAPAP
were synthesized, in which the P2 glycine residue was substituted by natural and unnatural amino acids. The thrombin inhibitory potency was comparable to that of
NAPAP
. Several of the compounds had inhibition constants lower than 10 nM and a very high selectivity compared to trypsin, factor Xa and
plasmin
. In addition, analogs were prepared by alkylation of the N(alpha)-atom of the 4-amidinophenylalanine in P1 position, which showed a more than 10-fold lower thrombin inhibition. Furthermore, azaglycine was introduced instead of P2 glycine. For most of the inhibitors similar fast elimination rates were seen in rats after intravenous dosing, as found previously for
NAPAP
. Only some compounds, which contained a second basic group showed a slightly decreased cumulative biliary clearance.
...
PMID:Structure-activity relationships of new NAPAP-analogs. 1169 44
The serine protease
plasmin
degrades extracellular matrix (ECM) components both directly and indirectly through activation of matrix metalloproteinases. Excessive
plasmin
activity and subsequent ECM degradation cause hepatic sinusoidal fragility and hemorrhage in developing embryos. We report here that excessive
plasmin
activity in a murine acetaminophen (
APAP
) overdose model likewise compromises hepatic sinusoidal vascular integrity in adult animals. We found that hepatic
plasmin
activity is up-regulated significantly at 6 hours after
APAP
overdose. This
plasmin
up-regulation precedes both degradation of the ECM component fibronectin around liver vasculature and bleeding from centrilobular sinusoids. Importantly, administration of the pharmacological
plasmin
inhibitor tranexamic acid or genetic reduction of plasminogen, the circulating zymogen of
plasmin
, ameliorates
APAP
-induced hepatic fibronectin degradation and sinusoidal bleeding. Conclusion: These studies demonstrate that reduction of
plasmin
stabilizes hepatic sinusoidal vascular integrity after
APAP
overdose. (Hepatology 2018; 00:1-13).
...
PMID:Excessive Plasmin Compromises Hepatic Sinusoidal Vascular Integrity After Acetaminophen Overdose. 2972 97